PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Gut dysbiosis and fecal microbiota transplantation in pancreatic cancer: Current status and perspectives

Gut dysbiosis and fecal microbiota transplantation in pancreatic cancer: Current status and perspectives
2024-11-07
(Press-News.org)

Pancreatic ductal adenocarcinoma (PDAC) is recognized as one of the most lethal cancers, with an estimated five-year survival rate of approximately 10%. This poor prognosis is largely attributed to the challenges in early diagnosis, aggressive tumor biology, and limited treatment options. Most PDAC cases are diagnosed at advanced stages due to its typically asymptomatic onset, making only a small percentage of patients eligible for potentially curative surgical resection. In recent years, increasing attention has been paid to the role of gut microbiota dysbiosis in PDAC, as it appears to influence disease progression, immune response, and therapeutic efficacy. Emerging studies suggest that manipulating the microbiome could present novel approaches to screening, diagnosing, and even treating PDAC. Among these strategies, fecal microbiota transplantation (FMT) shows promise as an adjunct therapy, potentially improving patient outcomes through microbiome modulation.

The Human Gut Microbiome
The human gut is home to trillions of microorganisms, forming a complex ecosystem that interacts with the host in numerous ways. This gut microbiota impacts various physiological processes, including immune regulation, nutrient absorption, and metabolism. A stable and diverse microbiota generally contributes to health, whereas shifts in microbial composition can lead to disease. Factors such as diet, lifestyle, age, and medication, especially antibiotics, influence the microbiome composition. Although defining a “healthy” gut microbiota is challenging due to individual variation, five primary bacterial phyla—Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Verrucomicrobia—are typically dominant. Dysbiosis, or microbial imbalance, is increasingly implicated in the onset and progression of diseases like PDAC, underscoring the need to explore gut microbiota's role in cancer and other systemic conditions.

Gut Dysbiosis in PDAC
Research highlights significant alterations in the gut microbiota composition of PDAC patients compared to healthy individuals. For instance, studies using stool samples have identified a higher abundance of Streptococcus and Veillonella species in PDAC patients, along with a notable decrease in beneficial strains such as Faecalibacterium prausnitzii. Such patterns suggest that specific microbial profiles may be associated with PDAC, potentially serving as biomarkers for diagnosis or even risk stratification. Other studies indicate an association between Helicobacter pylori infection and increased PDAC risk, suggesting that certain pathogenic bacteria could play a role in PDAC etiology. However, variations across studies point to the influence of geographic and ethnic factors on gut microbiota, highlighting the need for larger, multicenter studies to establish a comprehensive microbiome profile unique to PDAC patients.

Dysbiosis, Immune Regulation, and PDAC
The immune system’s interaction with the gut microbiota is complex, influencing both local and systemic immunity. In PDAC, gut dysbiosis may lead to an immune-suppressive microenvironment, enabling tumor growth. Studies demonstrate that microbial components, such as lipopolysaccharides from gram-negative bacteria, can activate immune pathways that influence tumor progression. For instance, experiments with PDAC models have shown that depleting the gut microbiota can reduce tumor growth, suggesting that certain bacterial populations might actively support an immunosuppressive state. Additionally, bacteria can translocate to the pancreas, where they modulate immune responses within the tumor microenvironment. These findings emphasize the potential of microbiota-based approaches to recalibrate immune responses in PDAC treatment.

Microbiota-Derived Metabolites and PDAC
Gut microbiota produces a variety of metabolites that affect the host’s physiological processes, including inflammation, immune responses, and even tumor cell behavior. Short-chain fatty acids (SCFAs), such as butyrate, are among the most researched microbial metabolites and have been shown to suppress PDAC cell invasiveness in laboratory settings. Other metabolites, including indole-3-acetic acid from Bacteroides species, have demonstrated potential to enhance chemotherapeutic efficacy in PDAC by modifying tumor cell responses to treatment. Notably, these metabolites may also stimulate immune cell function within the tumor microenvironment, offering another pathway through which microbiome-targeted therapies might benefit PDAC patients.

FMT in PDAC Treatment
Fecal microbiota transplantation (FMT) has shown efficacy in treating microbiota-related conditions, particularly in infections like Clostridioides difficile. In cancer therapy, FMT’s potential lies in its ability to restore a balanced gut microbiome, potentially improving immune surveillance and patient tolerance to treatments. Early preclinical studies involving PDAC mouse models reveal that FMT can influence tumor growth and immune infiltration. For example, PDAC-bearing mice receiving FMT from healthy donors displayed slower tumor progression compared to those transplanted with dysbiotic microbiota, underscoring the promise of FMT in modulating the tumor microenvironment.

Combining FMT with Cancer Treatments
Emerging evidence suggests that FMT may enhance the effectiveness of PDAC therapies such as chemotherapy and immunotherapy. The gut microbiota is known to impact drug metabolism and immune responses, which could influence treatment efficacy. For example, certain bacteria can inactivate gemcitabine, a standard chemotherapeutic for PDAC, thereby reducing its effectiveness. FMT could potentially counteract such microbial effects, restoring treatment sensitivity. Moreover, FMT has shown promise in mitigating adverse effects associated with immunotherapy and may hold potential in enhancing response rates in patients undergoing checkpoint blockade treatments. These findings underscore the potential of FMT as a valuable adjunct to current PDAC therapies.

Current Challenges and Perspectives in FMT for PDAC
While FMT holds considerable promise, its clinical application faces several challenges. One primary concern is the risk of transmitting infections from unscreened donors, as highlighted by cases of bacteremia linked to FMT. Rigorous donor screening protocols are essential to minimize such risks, as is continued research to standardize FMT procedures. Additionally, matching donors with recipients based on microbiome characteristics may enhance FMT effectiveness, although such precision-matching approaches are still under development. As research progresses, optimizing FMT protocols, addressing safety concerns, and establishing patient-specific strategies will be essential steps toward realizing FMT’s full potential in PDAC management.

 

Full text

https://www.xiahepublishing.com/2835-3315/CSP-2024-00017

 

The study was recently published in the Cancer Screening and Prevention.

Cancer Screening and Prevention (CSP) publishes high-quality research and review articles related to cancer screening and prevention. It aims to provide a platform for studies that develop innovative and creative strategies and precise models for screening, early detection, and prevention of various cancers. Studies on the integration of precision cancer prevention multiomics where cancer screening, early detection and prevention regimens can precisely reflect the risk of cancer from dissected genomic and environmental parameters are particularly welcome.

 

Follow us on X: @xiahepublishing

Follow us on LinkedIn:  Xia & He Publishing Inc.

 

END


[Attachments] See images for this press release:
Gut dysbiosis and fecal microbiota transplantation in pancreatic cancer: Current status and perspectives Gut dysbiosis and fecal microbiota transplantation in pancreatic cancer: Current status and perspectives 2

ELSE PRESS RELEASES FROM THIS DATE:

Prevalence of unrecognized cognitive impairment in socially and economically vulnerable older adults is high

2024-11-07
INDIANAPOLIS – One of the first studies to investigate the prevalence of unrecognized cognitive impairment among patients seen at Federally Qualified Health Centers, has found that it is ubiquitous, especially among minoritized older adults. These facilities provide primary care and preventive services regardless of ability to pay or health insurance status to more than 30 million patients, including a growing number of older adults. Early and equitable detection of cognitive impairment can benefit patients and their families. Delaying diagnosis leads to poor health outcomes for patients ...

Men who have sex with men in Europe still vulnerable to hepatitis A and B, highlighting need for public health action and support

Men who have sex with men in Europe still vulnerable to hepatitis A and B, highlighting need for public health action and support
2024-11-07
Research analysing European survey data from 113,884 men who have sex with men (MSM) and published in Eurosurveillance indicates that while most MSM have a basic understanding of viral hepatitis, only 44% report having been vaccinated against both hepatitis A and B.  The data highlight notable immunisation gaps despite available vaccination and recommendations. Strong public health support and creating an open environment that enables MSM to follow recommendations will be crucial to reduce outbreaks among MSM and eliminate hepatitis B. Men who have sex with men are more likely to get infected with ...

Cancer genetic risk assessment guidelines expand to meet growing understanding of hereditary risk

Cancer genetic risk assessment guidelines expand to meet growing understanding of hereditary risk
2024-11-07
PLYMOUTH MEETING, PA [November 7, 2024] — The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers focusing on maintaining evidence-based expert consensus driven guidelines for care—announces the publication of the expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. This closely follows the recent publication of the expanded NCCN Guidelines® for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric.  Additional cancer types were added to the title and content for both guidelines. ...

Advances in screening and early diagnosis of pancreatic cancer

Advances in screening and early diagnosis of pancreatic cancer
2024-11-07
Pancreatic cancer (PC) presents substantial diagnostic challenges due to its aggressive nature and lack of early symptoms, leading to late detection and poor prognosis. According to recent cancer statistics, PC ranks as the fourth leading cause of cancer deaths globally, with increasing incidence, particularly in high-risk regions such as China. Factors such as a shortage of specific and reliable screening markers, along with a lower prevalence in the general population, make effective large-scale screening a formidable tasko assess advancements in diagnostic techniques, artificial intelligence integration, biomarker discoveries, ...

Metabolic dysregulation and metabolite imbalances in acute-on-chronic liver failure: Impact on immune status

Metabolic dysregulation and metabolite imbalances in acute-on-chronic liver failure: Impact on immune status
2024-11-07
Acute-on-chronic liver failure (ACLF) is a life-threatening condition characterized by acute deterioration of liver function in patients with pre-existing chronic liver disease. It is often accompanied by multiorgan failure and systemic inflammation, with high short-term mortality rates. The triggers for ACLF include bacterial infections, acute alcoholic hepatitis, and ischemic hepatitis, leading to the release of pro-inflammatory mediators. These systemic inflammatory responses result in immune dysfunction, contributing to the progression of the disease​. Recent research has emphasized the metabolic changes ...

Elite coaches see compassion as a path to better performance

2024-11-07
It may sound like a contradiction to talk about compassion in the competitive world of elite sport. After all, isn't elite sport all about becoming hardened to resistance and adversity? But this is a false dichotomy, according to a new study that analysed the views of 12 Danish high-performance coaches on the use of compassion in their work with elite athletes. In fact, there is a broad consensus among the coaches, most of whom are head of national teams, about the benefits of using compassion, says the study's lead author, Emilia Backman from the Department of Psychology, University of Copenhagen. "All of the high-performance ...

Microplastics impact cloud formation, likely affecting weather and climate

Microplastics impact cloud formation, likely affecting weather and climate
2024-11-07
UNIVERSITY PARK, Pa. — Scientists have spotted microplastics, tiny pieces of plastic smaller than 5 millimeters, in some of the most pristine environments on Earth, from the depths of the Mariana Trench to the snow on Mt. Everest to the mountaintop clouds of China and Japan. Microplastics have been detected in human brains, the bellies of sea turtles and the roots of plants. Now, new research led by Penn State scientists reveals that microplastics in the atmosphere could be affecting weather and climate. The study, published today (Nov 7) in the journal Environmental Science and Technology: ...

ECOG-ACRIN and PrECOG announce multiple presentations at ASH 2024

2024-11-07
Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present a variety of abstracts that aim to improve treatments for patients with lymphoma and acute leukemias at the 66th American Society of Hematology (ASH) Meeting & Exposition. The meeting is set to occur in San Diego, California, and virtually December 7 - 10, 2024.   Promising results from a phase 2 study (PrE0905) in patients with acute myeloid leukemia and new data from the practice-changing E1910 phase ...

Off-the-shelf thermoelectric generators can upgrade CO2 into chemicals. The combination could help us colonize Mars

Off-the-shelf thermoelectric generators can upgrade CO2 into chemicals. The combination could help us colonize Mars
2024-11-07
Readily available thermoelectric generators operating under modest temperature differences can power CO2 conversion, according to a proof-of-concept study by chemists at the University of British Columbia (UBC). The findings open up the intriguing possibility that the temperature differentials encountered in an array of environments—from a typical geothermal installation on Earth to the cold, desolate surface of Mars—could power the conversion of CO2 into a range of useful fuels and chemicals. “The environment ...

What makes human culture unique?

2024-11-07
Why is human culture — the shared body of knowledge passed down across generations — so much more powerful than animal cultures?  “What’s special about our species?” is a question scientists have wrestled with for centuries, and now a scientist at Arizona State University has a new hypothesis that could change the way we perceive ourselves, and the world around us.  “Ten years ago it was basically accepted that it was the ability of human culture to accumulate and evolve that made us special, but new discoveries about animal behavior are challenging these ideas and forcing us to rethink what makes our cultures, ...

LAST 30 PRESS RELEASES:

DNA evidence rewrites story of people buried in Pompeii eruption

DNA evidence rewrites histories for people buried in volcanic eruption in ancient Pompeii

People with schizophrenia show distinct brain activity when faced with conflicting information

Climate change: Significant increase in carbon dioxide emissions from private aviation

Planting trees in the Arctic could make global warming worse, not better, say scientists

Finding function for noncoding RNAs using a new kind of CRISPR

Neurodevelopment in the first 2 years of life following prenatal exposure to maternal SARS-CoV-2 Infection

Racial disparities in genetic detection rates for inherited retinal diseases

Stem cells shed insight into cardiovascular disease processes 

New study: Plastics pollution worsen the impacts of all Planetary Boundaries

Long-term risks from prostate cancer treatment detailed in new report

Does more virtual care mean more low-value care? Study suggests no

City of Hope Research Spotlight, October 2024

Increased focus on comorbidities, socioeconomic factors would help improve health equity for people with COPD

Gut dysbiosis and fecal microbiota transplantation in pancreatic cancer: Current status and perspectives

Prevalence of unrecognized cognitive impairment in socially and economically vulnerable older adults is high

Men who have sex with men in Europe still vulnerable to hepatitis A and B, highlighting need for public health action and support

Cancer genetic risk assessment guidelines expand to meet growing understanding of hereditary risk

Advances in screening and early diagnosis of pancreatic cancer

Metabolic dysregulation and metabolite imbalances in acute-on-chronic liver failure: Impact on immune status

Elite coaches see compassion as a path to better performance

Microplastics impact cloud formation, likely affecting weather and climate

ECOG-ACRIN and PrECOG announce multiple presentations at ASH 2024

Off-the-shelf thermoelectric generators can upgrade CO2 into chemicals. The combination could help us colonize Mars

What makes human culture unique?

Researchers discover dozens of new genes associated with disc herniations

Research shows caterpillar fungus can slow down growth of cancer cells

Tanning bed access and usage is driving higher rates of melanoma in specific regions

Mitochondrial dysfunction research transforms mental health: Dr. Ana Andreazza's vision

Dr. Nora Volkow shares insights on addiction science and harm reduction in Genomic Press interview

[Press-News.org] Gut dysbiosis and fecal microbiota transplantation in pancreatic cancer: Current status and perspectives